MA47793A - Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque - Google Patents

Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque

Info

Publication number
MA47793A
MA47793A MA047793A MA47793A MA47793A MA 47793 A MA47793 A MA 47793A MA 047793 A MA047793 A MA 047793A MA 47793 A MA47793 A MA 47793A MA 47793 A MA47793 A MA 47793A
Authority
MA
Morocco
Prior art keywords
methyl
ylethynyl
hydrazide
quinoline
benzoyl
Prior art date
Application number
MA047793A
Other languages
English (en)
Inventor
Nitin Dharmadhikari
Bramhanand Hanamannavar
Yashoraj Zala
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MA47793A publication Critical patent/MA47793A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA047793A 2017-03-15 2018-03-15 Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque MA47793A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721005414 2017-03-15

Publications (1)

Publication Number Publication Date
MA47793A true MA47793A (fr) 2020-01-22

Family

ID=63521897

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047793A MA47793A (fr) 2017-03-15 2018-03-15 Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque

Country Status (8)

Country Link
US (2) US11351123B2 (fr)
EP (1) EP3596050A4 (fr)
JP (2) JP7234129B2 (fr)
CN (1) CN110494422A (fr)
AU (1) AU2018235446B2 (fr)
CA (1) CA3056348A1 (fr)
MA (1) MA47793A (fr)
WO (1) WO2018167802A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911040C (fr) 2012-05-02 2021-11-16 Georgetown University Traitement d'une synucleinopathie au moyen d'inhibiteurs de la tyrosine kinase
CN110494422A (zh) 2017-03-15 2019-11-22 太阳制药先进研究有限公司 4-甲基-3-喹啉-3-基乙炔基-苯甲酸n’-(2-氯-6-甲基-苯甲酰基)酰肼的新型无定形分散体
CN120040470A (zh) 2018-11-20 2025-05-27 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法
US20230301982A1 (en) * 2020-07-31 2023-09-28 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for treatment of alzheimer's disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034598B1 (ru) * 2005-12-23 2020-02-25 Ариад Фармасьютикалз, Инк. Применение бициклических гетероарильных соединений для лечения рака
CN103435595A (zh) * 2006-05-08 2013-12-11 阿里亚德医药股份有限公司 炔类杂芳基化合物
EP2089003A1 (fr) 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Forme de dosage pharmaceutique pour l'administration orale d'un inhibiteur de la tyrosine kinase
US9024021B2 (en) 2011-01-21 2015-05-05 Sun Pharma Advanced Research Company Ltd. Diarylacetylene hydrazide containing tyrosine kinase inhibitors
EP2802314B1 (fr) 2012-01-13 2020-11-25 XSpray Microparticles AB Procédé de production de nanoparticules hybrides amorphes stables comprenant au moins un inhibiteur de la protéine kinase et au moins un constituant polymère stabilisant et matriciel
CN105744847A (zh) * 2013-11-15 2016-07-06 帝斯曼知识产权资产管理有限公司 通过热熔挤出获得的略溶化合物的制剂
EP2913048A1 (fr) 2014-02-27 2015-09-02 ratiopharm GmbH Composition pharmaceutique comprenant de la trametinib
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
TWI803187B (zh) 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含4環性化合物的非晶質體之固體分散體及製劑
WO2016090240A1 (fr) * 2014-12-04 2016-06-09 Astex Pharmaceuticals, Inc. Compositions pharmaceutiques pour augmenter la biodisponibilité de médicaments faiblement solubles
CN110494422A (zh) 2017-03-15 2019-11-22 太阳制药先进研究有限公司 4-甲基-3-喹啉-3-基乙炔基-苯甲酸n’-(2-氯-6-甲基-苯甲酰基)酰肼的新型无定形分散体

Also Published As

Publication number Publication date
AU2018235446B2 (en) 2022-04-07
US20210267906A1 (en) 2021-09-02
US11351123B2 (en) 2022-06-07
CN110494422A (zh) 2019-11-22
RU2019132068A3 (fr) 2021-06-22
WO2018167802A9 (fr) 2019-02-07
JP2020510066A (ja) 2020-04-02
WO2018167802A1 (fr) 2018-09-20
JP7234129B2 (ja) 2023-03-07
JP2023027309A (ja) 2023-03-01
US20200085751A1 (en) 2020-03-19
EP3596050A4 (fr) 2021-01-13
US12194153B2 (en) 2025-01-14
EP3596050A1 (fr) 2020-01-22
JP7514292B2 (ja) 2024-07-10
AU2018235446A1 (en) 2019-10-03
CA3056348A1 (fr) 2018-09-20
RU2019132068A (ru) 2021-04-15

Similar Documents

Publication Publication Date Title
EP3897522A4 (fr) Compositions de microcapsules
EP3833739A4 (fr) Souche d'akkermansia muciniphila
PL3638666T3 (pl) Chwastobójczo skuteczne 3-fenyloizoksazolino-5-karboksyamidy amidów kwasu tetrahydro- i dihydrofuranokarboksylowego
EP3431075A4 (fr) Forme galénique d'édaravone
MX2018007022A (es) Metodos para tratar la enfermedad de huntington.
EP3478249A4 (fr) Compositions de microcapsules stables
EP3645146A4 (fr) Synthèse d'oligosaccharides
EP3600434A4 (fr) Traitement de l'hypertension pulmonaire
EP3407976A4 (fr) Compositions et utilisations d'agents alpha-adrénergiques
ECSP16093323A (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
MA42592A (fr) Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu'inhibiteurs de jak
EP3373969A4 (fr) Composés interagissant avec le glycane et méthodes d'utilisation
MA47179A (fr) Composition d'acide dicarboxylique mannuronique
EP3522882A4 (fr) Compositions d'acides aminés et utilisations associées
EP3589623C0 (fr) Preparation d' acide dicarboxylique de 2,5-furane
MA47793A (fr) Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque
EP3699245A4 (fr) Assortiment d'encres
MX378847B (es) Nuevos derivados de gamma-amanitina
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
EP3849527C0 (fr) Formulations de composés de cyclosérine et leurs applications
EP3585903C0 (fr) Production de caroténoïdes et d'apocaroténoïdes
CL2019002729A1 (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
EP3297674A4 (fr) Compositions de composé actif et benzamide et leurs méthodes d'utilisation
EP3302488A4 (fr) Nouvelle utilisation de dérivés aryl-quinoléine comme inhibiteurs de l'imitation de facteurs vasculogènes
EP4003323A4 (fr) Formulations stabilisées de dérivés de l'acide butanoïque du type 4-amino-3-substitués